Nanoscope Therapeutics and Catalent Expand Partnership for Optogenetic Gene Therapy MCO-010
Exciting news for the inherited retinal disease (IRD) community: Nanoscope Therapeutics and Catalent have announced an expanded partnership. This collaboration is focused on supporting the late-phase development and commercial supply of Nanoscope's lead optogenetic gene therapy candidate, MCO-010, according to a PR Newswire report published on July 7, 2026.
This development is particularly significant for individuals living with IRDs because MCO-010 is an investigational optogenetic gene therapy. Optogenetic therapies aim to restore vision by making retinal cells light-sensitive, offering a potential therapeutic approach for a broad range of IRDs, regardless of the specific underlying gene mutation. The expansion of this partnership suggests a commitment to advancing MCO-010 through its final stages of development and preparing for potential availability.
Catalent, a global contract development and manufacturing organization, will continue to provide manufacturing services for MCO-010. This expanded agreement builds upon their existing relationship, which began in 2021. The continued collaboration with an established manufacturer like Catalent is a crucial step in ensuring that if MCO-010 proves safe and effective and receives regulatory approval, there will be a robust supply chain in place to meet patient needs.
For patients and families affected by IRDs, this partnership represents progress in the journey towards new treatment options. While MCO-010 is still an investigational therapy, the focus on late-phase development and commercial supply indicates that Nanoscope Therapeutics is moving closer to potentially bringing this therapy to those who could benefit. The commitment to manufacturing scale-up is a positive sign for the future accessibility of this potential treatment.
The expanded partnership between Nanoscope Therapeutics and Catalent underscores the ongoing efforts within the biotech industry to develop and prepare for the delivery of innovative therapies for inherited retinal diseases. The community will be watching for further updates on MCO-010's progress.